Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:D01AE25
|
| gptkbp:brand |
gptkb:Kerydin
|
| gptkbp:CASNumber |
gptkb:174671-46-6
|
| gptkbp:chemicalClass |
boron-containing compound
|
| gptkbp:developer |
gptkb:Anacor_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
gptkb:C7H6BFO2
|
| gptkbp:hasSMILES |
B1(C2=CC=CC=C2O1)F
|
| https://www.w3.org/2000/01/rdf-schema#label |
tavaborole
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits fungal leucyl-tRNA synthetase
|
| gptkbp:molecularWeight |
151.93 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105757
11287817 9450737 |
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
application site dermatitis
application site erythema application site exfoliation application site pain |
| gptkbp:UNII |
6Z1Y2V4S2E
|
| gptkbp:usedFor |
treatment of onychomycosis
|
| gptkbp:bfsParent |
gptkb:Anacor_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|